Keyphrases
Non-small Cell Lung Cancer (NSCLC)
88%
Lung Cancer
49%
Small Cell Lung Cancer
41%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
34%
Confidence Interval
33%
Overall Survival
32%
Phase II Study
30%
Chemotherapy
29%
Phase I Trial
20%
Targeted Therapy
19%
Circulating Tumor DNA (ctDNA)
19%
Phase II Trial
18%
Solid Tumors
18%
Previously Treated
18%
Atezolizumab
15%
Radiotherapy
15%
Immune Checkpoint Inhibitors
14%
Phase I Study
14%
Partial Response
13%
Brain Metastases
12%
Adjuvant Chemotherapy
12%
Clinical Trials
12%
National Cancer Database
12%
Hazard Ratio
12%
Patients with Cancer
12%
Resectable Lung Cancer
11%
Durvalumab
11%
Temsirolimus
11%
Squamous Cell Lung Cancer
11%
Chemoradiation
11%
Platinum-based Chemotherapy
11%
Stable Disease
11%
Progression-free Survival
11%
Patient Selection
10%
Recommended Phase 2 Dose
10%
Surgical Resection
10%
Maximum Tolerated Dose
10%
Advanced Solid Tumors
10%
Radiation Therapy
10%
Neoadjuvant
9%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
9%
Surveillance Epidemiology
9%
Cancer mutations
9%
Twice Daily
9%
Lung Adenocarcinoma
9%
Once-daily
9%
Histology
8%
Response Rate
8%
Tumor
8%
Median Overall Survival
8%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Lung Cancer
56%
Overall Survival
38%
Small Cell Lung Cancer
37%
Neoplasm
26%
Diseases
26%
Arm
24%
Radiation Therapy
24%
Surgery
23%
Malignant Neoplasm
20%
Circulating Tumor DNA
17%
Phase II Trials
17%
Targeted Therapy
16%
Atezolizumab
15%
Adverse Event
15%
Solid Malignant Neoplasm
14%
Progression Free Survival
14%
Chemoradiotherapy
13%
Durvalumab
11%
Squamous Cell Lung Carcinoma
11%
Brain Metastasis
11%
Immunotherapy
11%
Lung
11%
Systemic Therapy
11%
Non-Small Cell Lung Cancer
11%
Surveillance, Epidemiology, and End Results
9%
Adjuvant Chemotherapy
9%
Immune Checkpoint Inhibitor
8%
Etoposide
8%
Hazard Ratio
7%
Influenza Vaccination
7%
Clinical Oncology
7%
Pneumonia
7%
Epidermal Growth Factor Receptor
7%
Clinical Trial
7%
Tyrosine-Kinase Inhibitor
7%
Odds Ratio
5%
Base
5%
Symptomatic Treatment
5%
Next Generation Sequencing
5%
Biological Marker
5%
Medicine
5%
Neoadjuvant Therapy
5%
Adenocarcinoma
5%
Lung Adenocarcinoma
5%
Supportive Care
5%
Oncology
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
70%
Lung Cancer
57%
Chemotherapy
36%
Small Cell Lung Cancer
36%
Overall Survival
31%
Solid Malignant Neoplasm
30%
Diseases
28%
Neoplasm
24%
Malignant Neoplasm
24%
Adverse Event
15%
Progression Free Survival
13%
Chemoradiation Therapy
12%
Immune Checkpoint Inhibitor
12%
Phase I Trials
12%
Brain Metastasis
12%
Durvalumab
11%
Squamous Cell Lung Carcinoma
11%
Immunotherapy
11%
Clinical Trial
10%
Etoposide
9%
Protein Tyrosine Kinase Inhibitor
9%
Phase II Trials
9%
Carboplatin
8%
Temsirolimus
7%
Circulating Tumor DNA
7%
Pemetrexed
7%
Placebo
7%
Maximum Tolerated Dose
7%
Paclitaxel
7%
Neuroendocrine Tumor
7%
Antitumor Activity
7%
Pneumonia
6%
Antibody Drug Conjugate
6%
Ensartinib
6%
Pharmacokinetics
6%
Inflammation
5%
Biological Marker
5%
Glioblastoma
5%
Squamous Cell Carcinoma
5%
Cisplatin
5%
Erlotinib
5%